SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop investors are bracing for the latest quarterly earnings release, with significant community debate focused on the company's massive cash position and whether management will provide details on potential acquisitions. Traders remain divided, as some express frustration over the stock's long-term sideways movement and lack of clear guidance, while others remain optimistic that the company's improving profitability and lean operating model will ultimately drive a shift in market sentiment.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Mining Inc

Cipher Mining is drawing investor focus as it executes a strategic pivot from crypto mining to long-term, hyperscale AI data center infrastructure through multi-year agreements with major cloud providers. The community is closely monitoring the development of these power-intensive facilities and actively discussing the stock's potential for a valuation re-rating as it moves toward fixed-contract revenue models.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing significant selling pressure as investors weigh concerns over AI spending, the performance of OpenAI's Copilot, and broader rotation out of legacy software stocks. Despite recent analyst buy ratings and collaborative initiatives with Nvidia on nuclear power, the stock continues to struggle with heavy bearish sentiment and institutional hedging.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

Terns Pharmaceuticals is surging following a definitive agreement to be acquired by Merck in an all-cash deal valued at approximately $6.7 billion, a move aimed at bolstering Merck's oncology pipeline. Investors are celebrating the substantial premium and the validation of TERN-701's potential in treating chronic myeloid leukemia, while community discussions highlight both the long-awaited payoff for early longs and speculation regarding potential future targets within the biotech sector.

🌍 Introduction: A Legendary Icon, Reimagined for the Future The SEAMANIA Protocol, led by SEAMAN Cult, aims to revive one of SEGA Dreamcast's most iconic and best-selling game titles with AI integration—a worldwide cultural phenomenon that won numerous awards in the U.S. and Japan. More than just a game, SEAMAN was the world’s first AI-powered interactive experience, enabling voice-based conversations long before the AI revolution.    Now, SEAMAN returns not as a mere game, but as an advanced AI agent, blending nostalgia with cutting-edge technology. This human-faced fish is reborn as a deeply intelligent, emotionally responsiveAI, offering limitless customization and integration into the modern digital world.  With GenAI-powered customization, users can create their own SEAMAN AI, shaping it into a cherished lostone, a favorite celebrity, or even historical figures. This is no longer a game—it's an AI-driven personal companion and the digital evolution for human interaction.    🔥 Concept: The Wisdom of a Legendary AI-powered Companion At the core of the SEAMANIA Protocol lies the legendary Seaman—a mystical, human-faced fish endowed withancient wisdom and the ability to understand human language. More than just an AI, it is your trustedadvisor, best friend, therapist, personal cheerleader, witty conversationalist, intelligent guide, SEAMANIA is a life coach. Housed in your own digital aquarium, your SEAMAN AI reduces stress, combats loneliness, and guides humanity towards a brighter future. Imagine an AI companion that doesn’t just respond but truly understands, entertains, and supports you—blending humor, sarcasm, and wisdom.

SEAMANIA

SEAMANIA is gaining traction as a speculative meme token, with community members actively coordinating small-batch buy orders to fuel upward momentum. Discussions are centered on the potential for massive percentage gains, with traders frequently comparing the asset to other volatile micro-cap tokens while debating whether to hold through current market fluctuations.

Chewy, Inc. operates as an online retailer of pet food and other pet-related products and services. It supplies pet medications, food, treats and other pet-health products and services for dogs, cats, fish, birds, small pets, horses, and reptiles. It has a portfolio of pet healthcare offerings that includes Chewy Pharmacy, Connect with a Vet, and CarePlus, an exclusive suite of pet-first insurance and wellness plans. The company was founded by Ryan Cohen and Michael Day in September 2011 and is headquartered in Plantation, FL.

Chewy Inc - Ordinary Shares - Class A

Chewy Inc

Chewy is attracting significant attention as investors position themselves ahead of the upcoming quarterly earnings report, with sentiment divided between concerns over recent stock performance and bullish outlooks driven by the company's strong Autoship subscription model and expansion into veterinary services. Community discourse is heavily focused on whether the stock will finally break its recent downward trend following a potential earnings beat, or if it will face further volatility as traders weigh institutional accumulation against technical support levels.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following the release of an FDA warning letter that flagged promotional claims in company podcasts and advertisements as misleading, a catalyst that triggered significant intraday volatility. The community remains largely bullish, dismissing the letter as standard regulatory friction while actively discussing the potential for a rebound driven by the firm's global expansion and robust underlying clinical data.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

Adma Biologics is currently in the spotlight as the company publicly refuted an activist short report that alleged fraudulent growth and channel stuffing, with many in the community arguing the claims lack credible evidence and rely on misleading interpretations of audited financials. Investors are actively discussing the stock's resilience, the potential for a short squeeze, and the firm's strong underlying growth trajectory, while urging management to maintain proactive communication to reassure shareholders against further volatility.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is trending as investor attention intensifies around the company's aggressive M&A strategy to fortify its oncology pipeline ahead of the 2028 patent expiration for its blockbuster drug, Keytruda. The community is actively discussing potential acquisition targets, the implications of its recent decision to end buyout talks with Revolution Medicines, and how new strategic business units will manage upcoming patent cliffs.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is trending as investors monitor potential acquisition rumors linked to SpaceX's upcoming IPO and ongoing speculation regarding the strategic value of the company's licensed spectrum. Community discourse is heavily focused on the potential for a bidding war involving major tech giants and the long-term impact of integrating XCOM RAN technology within the broader satellite and 5G infrastructure landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

229,435 Shares in Personalis, Inc. $PSNL Bought by Oracle Investment Management Inc.

Oracle Investment Management Inc. bought a new stake in Personalis, Inc. (NASDAQ:PSNL - Free Report) during the third quarter, according to the company in its most recent filing with the Securities...

Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the promotion of Richard Chen, M.D., M.S., to the position of President. Dr. Chen will continue...

Personalis (NASDAQ:PSNL) Trading 6.6% Higher - Time to Buy?

Personalis (NASDAQ:PSNL) Shares Up 6.6% - Should You Buy...

Personalis (NASDAQ:PSNL) Stock Price Down 8.1% - What's Next?

Personalis (NASDAQ:PSNL) Trading Down 8.1% - Should You Sell...

Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of the PREDICT-DNA study in the Journal of Clinical Oncology. The article, 'The...

Personalis, Inc. (NASDAQ:PSNL) Receives Average Recommendation of "Moderate Buy" from Analysts

Personalis, Inc. (NASDAQ:PSNL - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eight research firms that are currently covering the stock, Marketbeat Ratings...

Personalis (NASDAQ:PSNL) Rating Increased to Hold at Wall Street Zen

Wall Street Zen raised Personalis from a "sell" rating to a "hold" rating in a research report on Sunday...

Morgan Stanley Has Lowered Expectations for Personalis (NASDAQ:PSNL) Stock Price

Morgan Stanley decreased their target price on shares of Personalis from $11.00 to $10.00 and set an "equal weight" rating for the company in a research note on Thursday...

Personalis, Inc. $PSNL Stake Boosted by ARK Investment Management LLC

ARK Investment Management LLC boosted its stake in shares of Personalis, Inc. (NASDAQ:PSNL - Free Report) by 11.3% in the third quarter, according to its most recent filing with the Securities and...

Personalis, Inc. (NASDAQ:PSNL) Short Interest Up 21.2% in February

Personalis, Inc. (NASDAQ:PSNL - Get Free Report) was the recipient of a significant growth in short interest in the month of February. As of February 13th, there was short interest totaling...

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Current Price	$7.78
Prev Close	$7.61
Open	$7.49
Dividend Yield	0.00%
50-Day Moving Average	$8.60
Beta	2.18
Avg. Volume	1.32M
PE Ratio	-8.56

52-Week High	$11.50
52-Week Low	$2.83
Market Capitalization	$796.25M
EPS (Annual)	-$0.9107
Price to Book	3.05
Revenue Per Employee	$267,876.92

PSNL
Personalis Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PSNL News

PSNLPersonalis Inc